Under 10% of people eligible to benefit from weight-loss injections such as Wegovy can access them, caution the World Health Organization as it issues its first recommendations on the medications.
Considering in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
Per forecasts, over two billion are projected to be living with obesity by 2030 unless action is taken.
"Our new guidance acknowledges that obesity is a lifelong illness that can be addressed with holistic and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and logistical bottlenecks are major barriers to universal access to the injections that can assist patients in reducing substantial body mass, explains the agency.
GLP-1 Therapy Shortage
Despite the present most favorable outlook, the supply of these medications could only cover around 100 million people – fewer than 10% of those who need them, according to the WHO.
The advice urges governments and firms to expand access, via approaches such as voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is scheduled to end in a number of countries in 2026.
The Way Obesity Injections Operate
GLP-1 drugs mimick a body's own hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so users eat less.
People usually begin shedding pounds after several weeks of starting on the weekly injections.
Evidence points to patients may see weight return after a year of halting the drug, as their typical food cravings come back.
To be overweight or obese elevates your likelihood for developing medical conditions, including diabetes, heart disease, brain attack, and certain cancers.
Obesity impacts people in countries worldwide and was linked to millions of deaths worldwide in 2024, according to the WHO.
